Ken Griffin Merck & Co., Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$111.15 - $128.97 $28.5 Million - $33 Million	256,200 Added 10.51%	2,694,300 $306 Million
Q2 2024 Aug 14, 2024	SELL	$123.8 - $132.96 $49.3 Million - $52.9 Million	-397,900 Reduced 14.03%	2,438,100 $302 Million
Q1 2024 May 15, 2024	BUY	$113.24 - $131.95 $11.9 Million - $13.9 Million	105,300 Added 3.86%	2,836,000 $374 Million
Q4 2023 Feb 14, 2024	SELL	$100.18 - $109.02 $3.72 Million - $4.04 Million	-37,100 Reduced 1.34%	2,730,700 $298 Million
Q3 2023 Nov 14, 2023	BUY	$102.95 - $114.33 $53.5 Million - $59.4 Million	519,600 Added 23.11%	2,767,800 $285 Million
Q2 2023 Aug 14, 2023	SELL	$108.61 - $118.38 $26.8 Million - $29.2 Million	-246,800 Reduced 9.89%	2,248,200 $259 Million
Q1 2023 May 15, 2023	SELL	$102.94 - $114.86 $113 Million - $126 Million	-1,092,900 Reduced 30.46%	2,495,000 $265 Million
Q4 2022 Feb 14, 2023	SELL	$87.44 - $112.11 $16.9 Million - $21.6 Million	-193,000 Reduced 5.1%	3,587,900 $398 Million
Q3 2022 Nov 14, 2022	BUY	$84.53 - $94.96 $68.6 Million - $77.1 Million	811,400 Added 27.32%	3,780,900 $326 Million

3,819

1.88B

15.6M

13.7M

Ticker MRK
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,533,280,000
Market Cap $247B
Description
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.